Low dose ATG-Fresenius for GVHD prophylaxis: a comparative study with ATG-Thymoglobulin
This study highlights the safety and efficacy of low-dose ATG-F compared to a relatively high dose ATG-T. Prospective studies are necessary to validate the safety and efficacy of low dose ATG-F for GVHD prevention.
Authors
- Sigal Grisariu (ORCID: https://orcid.org/0000-0001-7190-6326)
- Polina Stepensky (ORCID: https://orcid.org/0000-0002-4923-3660)
- Boaz Nachmias (ORCID: https://orcid.org/0000-0002-7341-2167)
- Batia Avni (ORCID: https://orcid.org/0000-0001-8516-2751)
- Adir Shaulov (ORCID: https://orcid.org/0000-0002-9620-781X)
- Shlomo Elias (ORCID: https://orcid.org/0000-0002-5055-5317)
- Eran Zimran (ORCID: https://orcid.org/0000-0002-5483-5180)
- Itai Falicovich
Institutions
- Hebrew University of Jerusalem (IL)
- Hadassah Medical Center (IL)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-01-27
- DOI
- https://doi.org/10.3389/fimmu.2025.1526513
- Citations
- 2
- Primary Topic
- Hematopoietic Stem Cell Transplantation
- Type
- article
- Field-Weighted Citation Impact
- 3.54